E-LIB Suche - Ergebnisse für: Heist, Rebecca S

1

Phase I/II Study of Combined BCL-xL and MEK Inhibition with..:

Corcoran, Ryan B. ; Do, Khanh T. ; Kim, Jeong E....
Clinical Cancer Research. 30 (2024) 9 - p. 1739-1749 , 2024

Link: https://doi.org/10.1158/..

2

Clinical management, monitoring, and prophylaxis of adverse..:

Heist, Rebecca S. ; Sands, Jacob ; Bardia, Aditya...
Cancer Treatment Reviews. 125 (2024) - p. 102720 , 2024

Link: https://doi.org/10.1016/..

3

Activating Point Mutations in the MET Kinase Domain Represe..:

Pecci, Federica ; Nakazawa, Seshiru ; Ricciuti, Biagio...
Cancer Discovery. , 2024

Link: https://doi.org/10.1158/..

4

Transport of carboxylate salts of varying chain lengths in ..:

Mazumder, Antara ; Heist, Alexandra ; Beckingham, Bryan S.
Journal of Membrane Science. 699 (2024) - p. 122584 , 2024

Link: https://doi.org/10.1016/..

5

8MO Adagrasib (MRTX849) in patients with advanced/metastati..:

Jänne, P.A. ; Spira, A. ; Riely, G.J....
Journal of Thoracic Oncology. 18 (2023) 4 - p. S41-S42 , 2023

Link: https://doi.org/10.1016/..

6

Efficacy and Tolerability of ALK/MET Combinations in Patien..:

Dagogo-Jack, Ibiayi ; Kiedrowski, Lesli A. ; Heist, Rebecca S....
JTO Clinical and Research Reports. 4 (2023) 8 - p. 100534 , 2023

Link: https://doi.org/10.1016/..

7

CTIM-02. PHASE 2 TRIAL OF PEMBROLIZUMAB FOR PATIENTS WITH B..:

Brastianos, Priscilla ; Kim, Albert ; Giobbe-Hurder, Anita...
Neuro-Oncology. 25 (2023) Supplement_5 - p. v60-v61 , 2023

Link: https://doi.org/10.1093/..

8

OA19.05 Activating MET Tyrosine Kinase Domain Mutations as ..:

Nakazawa, S. ; Pecci, F. ; Ricciuti, B....
Journal of Thoracic Oncology. 18 (2023) 11 - p. S88-S89 , 2023

Link: https://doi.org/10.1016/..

9

Abnormal vascular structure and function within brain metas..:

Kim, Albert E ; Lou, Kevin W ; Giobbie-Hurder, Anita...
Neuro-Oncology. 26 (2023) 5 - p. 965-974 , 2023

Link: https://doi.org/10.1093/..

10

Safety and clinical activity of atezolizumab plus erlotinib..:

Rudin, C.M. ; Cervantes, A. ; Dowlati, A....
ESMO Open. 8 (2023) 2 - p. 101160 , 2023

Link: https://doi.org/10.1016/..

11

Pembrolizumab in brain metastases of diverse histologies: p..:

Brastianos, Priscilla K. ; Kim, Albert E. ; Giobbie-Hurder, Anita...
Nature Medicine. , 2023

Link: https://doi.org/10.1038/..

12

Patient-reported outcomes in capmatinib-treated patients wi..:

Wolf, Jürgen ; Garon, Edward B. ; Groen, Harry J.M....
European Journal of Cancer. 183 (2023) - p. 98-108 , 2023

Link: https://doi.org/10.1016/..

13

Improved Survival Outcomes in Patients With MET-Dysregulate..:

Wolf, Jürgen ; Souquet, Pierre-Jean ; Goto, Koichi...
Clinical Lung Cancer. 24 (2023) 7 - p. 641-650.e2 , 2023

Link: https://doi.org/10.1016/..

14

MA06.04 KRYSTAL-1: Two-Year Follow-Up of Adagrasib (MRTX849..:

Gadgeel, S. ; Jänne, P.A. ; Spira, A.I....
Journal of Thoracic Oncology. 18 (2023) 11 - p. S118 , 2023

Link: https://doi.org/10.1016/..

15

Multicenter experience with andexanet alfa for refractory p..:

Zghaib, Tarek ; Allison, John D. ; Barrett, Christopher...
Journal of Cardiovascular Electrophysiology. 34 (2023) 3 - p. 593-597 , 2023

Link: https://doi.org/10.1111/..